Impact of HBV therapy on the incidence of hepatocellular carcinoma.
about
Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis.Assessment of high-sensitivity C-reactive protein tests for the diagnosis of hepatocellular carcinoma in patients with hepatitis B-associated liver cirrhosis.Primary biliary acids inhibit hepatitis D virus (HDV) entry into human hepatoma cells expressing the sodium-taurocholate cotransporting polypeptide (NTCP).Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.Cholecystectomy is associated with higher risk of early recurrence and poorer survival after curative resection for early stage hepatocellular carcinoma.Managing hepatitis B to prevent liver cancer: recent advances.Report from European Association for the Study of the Liver: HCC Summit, Geneva, Switzerland, 2-5 February 2017.Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir.Intermediate-stage hepatocellular carcinoma patients with a high HBV-DNA load may benefit from postoperative anti-hepatitis B virus therapy.Positive HBcAb is associated with higher risk of early recurrence and poorer survival after curative resection of HBV-related HCC.Liver stiffness-based model for prediction of hepatocellular carcinoma in chronic hepatitis B virus infection: comparison with histological fibrosis.Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B.Predictive value of the preoperative neutrophil-to-lymphocyte ratio for the development of hepatocellular carcinoma in HBV-associated cirrhotic patients after splenectomy.Resource utilization and survival among Medicare patients with advanced liver disease.
P2860
Q30251618-7E8FA2B7-609A-474A-9EC4-E57FE9FA7963Q33684950-4228FE3C-FC3C-421A-817D-B99742F44604Q35043978-FFC21625-8763-40E9-88CB-38BAF89C93B2Q35843093-C994928A-C1E8-46C9-9D23-BA8AEE53081DQ37019454-5EF750F9-49D2-46B8-879D-FD83FC4BB3D1Q38192050-A6FECEFF-1FE2-4DD4-9A8C-56CBBACDBC39Q38673823-3AFC2BE5-8317-4796-AC43-7EC07D3C4A49Q38698073-2029295B-FE32-43B4-8BDB-F675E77B4A54Q40107680-C460654D-8A45-47C1-957B-326866F69D2DQ40806597-4F8907D0-69A2-4512-AB2E-F8D3371A25A7Q42212445-6102581F-1AEC-4331-9CAE-E1B3F2F03D30Q47890590-D8844464-9F69-416A-B794-1D965C033AC8Q52604610-34CD3125-88D2-4E17-B6B0-DD43A1BC8D48Q53085800-43AB9398-413C-47DC-9811-435ECEE131CC
P2860
Impact of HBV therapy on the incidence of hepatocellular carcinoma.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Impact of HBV therapy on the incidence of hepatocellular carcinoma.
@en
type
label
Impact of HBV therapy on the incidence of hepatocellular carcinoma.
@en
prefLabel
Impact of HBV therapy on the incidence of hepatocellular carcinoma.
@en
P2093
P2860
P356
P1433
P1476
Impact of HBV therapy on the incidence of hepatocellular carcinoma.
@en
P2093
Cristina Della Corte
Massimo Colombo
Michela Triolo
P2860
P304
P356
10.1111/LIV.12394
P478
34 Suppl 1
P577
2014-02-01T00:00:00Z